New animal model Development
One of the limitations of preclinical efficacy evaluation is the lack of appropriate animal models covering important aspects of the human disease. On the other hand, humanization of drugable targets offers a valuable tool for the preclinical evaluation of human therapeutics and especially of biologics. The development of new transgenic mice carrying selected human molecular targets that are good candidates for novel therapeutic approaches is one of our major research activities.
The most recent example of our activities towards this direction is the generation of transgenic mice carrying the human IL17A gene. These animals used in combination with the Imiquimod psoriasis model, offer a valuable and unique genetic tool for the evaluation of anti-hIL17A therapeutics targeting human psoriasis.
For us at Biomedcode, research and development is one of our most important activities. Being a CRO spin-off company of the research institute BSRC “Alexander Fleming” and having in our portfolio transgenic mouse models that have been products of several years’ research activities shedding light in the mechanisms of the pathophysiology of human rheumatoid arthritis, we are passionately involved in a variety of Research and Development activities that aim to lead to innovative approaches in our field.